Full Press Release Details
argenx announces results of Annual General Meeting
Breda, the Netherlands - argenx
SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune
diseases and cancer, today announced that the proposed resolutions presented at its Annual General Meeting of Shareholders, held today
at 10:00 a.m. CEST, were duly passed.
As part of the approved resolutions:
In line with previous announcements, Dr. David Lacey has today resigned
from the board of directors and will transition to an advisory role for the company.
The results of the votes and all documents relating
to the shareholders' meeting will be available on the Company's website at www.argenx.com.
argenx is a global immunology company committed
to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through
its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based
medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration
with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices
For further information, please contact:
Forward-looking Statements
The contents of this announcement include statements
that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the
use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects,"
"intends," "may," "will," or "should" and include statements argenx makes concerning its
2021 business and financial outlook and related plans; the therapeutic potential of its product candidates; the intended results
of its strategy and argenx's, and its collaboration partners', advancement of, and anticipated clinical development,
data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; the design
of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature,
forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not
guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking
statements as a result of various important factors, including the effects of the COVID-19 pandemic, argenx's expectations
regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development
activities and regulatory approval requirements; argenx's reliance on collaborations with third parties; estimating the
commercial potential of argenx's product candidates; argenx's ability to obtain and maintain protection
of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability
to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further
list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange
Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC
as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this
document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking
statements, except as may be required by law.